0001140361-11-048592.txt : 20111006
0001140361-11-048592.hdr.sgml : 20111006
20111006132320
ACCESSION NUMBER: 0001140361-11-048592
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20111004
FILED AS OF DATE: 20111006
DATE AS OF CHANGE: 20111006
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AYERS JONATHAN W
CENTRAL INDEX KEY: 0001184149
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19271
FILM NUMBER: 111128803
MAIL ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE
CENTRAL INDEX KEY: 0000874716
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 010393723
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092-2041
BUSINESS PHONE: 2075560300
MAIL ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092-2041
FORMER COMPANY:
FORMER CONFORMED NAME: IDEXX CORP / DE
DATE OF NAME CHANGE: 19600201
4
1
doc1.xml
FORM 4
X0304
4
2011-10-04
0
0000874716
IDEXX LABORATORIES INC /DE
IDXX
0001184149
AYERS JONATHAN W
ONE IDEXX DRIVE
WESTBROOK
ME
04092
1
1
0
0
CHAIRMAN, PRESIDENT & CEO
Common Stock
2011-10-04
4
M
0
20000
12.6
A
317697
D
Common Stock
2011-10-04
4
S
0
9500
64.2054
D
308197
D
Common Stock
2011-10-04
4
S
0
5500
64.5939
D
302697
D
Common Stock
2011-10-05
4
M
0
20000
12.6
A
322697
D
Common Stock
2011-10-05
4
S
0
14597
66.1209
D
308100
D
Common Stock
2011-10-05
4
S
0
403
66.7387
D
307697
D
Non-Qualified Stock Option (right to buy)
12.60
2011-10-04
4
M
0
20000
0
D
2012-01-28
Common Stock
20000
100320
D
Non-Qualified Stock Option (right to buy)
12.6
2011-10-05
4
M
0
20000
0
D
2012-01-28
Common Stock
20000
80320
D
Includes 79 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 09/30/2011.
The reported sale above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/03/2011.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $63.88 to $64.85, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $65.00 to $65.43, inclusive.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $65.66 to $66.57, inclusive.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $66.69 to $66.75, inclusive.
Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (01/28/2003) of the date of grant.
Conan R. Deady, Attorney-in-Fact for Jonathan W. Ayers
2011-10-06